2026-09-21T00:08:02Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/372312022-01-13T07:54:52Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Arnoldo Hax.
Reynolds, Francis M., M.B.A. Massachusetts Institute of Technology
Sloan School of Management.
Sloan School of Management
2007-04-20T15:54:36Z
2007-04-20T15:54:36Z
2006
2006
http://hdl.handle.net/1721.1/37231
85822414
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management, 2006.
Includes bibliographical references (leaf 100).
To date, the primary treatment for spinal cord injuries has been the use of spinal fixation devices to create a stable environment for the spinal cord to heal. The second treatment option is to remove soft tissue near and around the spinal cord intended to reduce pressure on the spinal cord and allow the spinal cord to heal on its own. InVivo Therapeutics Corporation is a startup founded to commercialize novel science and technology that was developed through a collaborative effort between the Massachusetts Institute of Technology's Langer labs, and the department of Neuroscience at Harvard Medical School. Together they have created a patent pending medical device that will provide the first "Neuro-Tissue Engineered" implantable device for the immediate treatment of spinal cord injuries. We expect to have our first product on the market in 2010, and we will continue to work in our labs to develop a portfolio of three to four product categories in order to meet the systemic needs of the spinal cord injury patient. This thesis presents the first business plan, to commercialize this innovative treatment option.
(cont.) It is always challenging to be first to market with such an innovative product, so we have meticulously explored all relevant strategic initiatives, and tactical tasks required to bring our products to market. As the result we have developed a comprehensive business plan to ensure InVivo's success. Key components of the plan are: Introduction to InVivo Therapeutics, InVivo's business model, critical strategic analysis, functional strategies, financial analysis, and an integrative strategic framework. We have created a vision, mission, and strategic model that will lead to InVivo Therapeutics becoming a global leader in the treatment of neurological disease.
by Francis M. Reynolds.
M.B.A.
100 leaves
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Sloan School of Management.
InVivo Therapeutics® Corporation
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="388f75b0-8a6e-4da3-b4fb-b12df8187f8e">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>InVivo Therapeutics® Corporation</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2006</PublicationDate>
<Authors>
<Author>
<DisplayName>Reynolds, Francis M., M.B.A. Massachusetts Institute of Technology</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Sloan School of Management.</Keyword>
<Abstract>To date, the primary treatment for spinal cord injuries has been the use of spinal fixation devices to create a stable environment for the spinal cord to heal. The second treatment option is to remove soft tissue near and around the spinal cord intended to reduce pressure on the spinal cord and allow the spinal cord to heal on its own. InVivo Therapeutics Corporation is a startup founded to commercialize novel science and technology that was developed through a collaborative effort between the Massachusetts Institute of Technology's Langer labs, and the department of Neuroscience at Harvard Medical School. Together they have created a patent pending medical device that will provide the first "Neuro-Tissue Engineered" implantable device for the immediate treatment of spinal cord injuries. We expect to have our first product on the market in 2010, and we will continue to work in our labs to develop a portfolio of three to four product categories in order to meet the systemic needs of the spinal cord injury patient. This thesis presents the first business plan, to commercialize this innovative treatment option.</Abstract>
<Abstract>(cont.) It is always challenging to be first to market with such an innovative product, so we have meticulously explored all relevant strategic initiatives, and tactical tasks required to bring our products to market. As the result we have developed a comprehensive business plan to ensure InVivo's success. Key components of the plan are: Introduction to InVivo Therapeutics, InVivo's business model, critical strategic analysis, functional strategies, financial analysis, and an integrative strategic framework. We have created a vision, mission, and strategic model that will lead to InVivo Therapeutics becoming a global leader in the treatment of neurological disease.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>